ClearPoint Neuro, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M | $11.1M |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M | -$13.4M |
| Cost of revenue | $14.3M | $12.3M | $10.3M | $7.0M | $5.2M |
| Cash from operations | -$23.9M | -$8.9M | -$13.7M | -$16.2M | -$12.7M |
| Capital expenditure | $522,000 | $275,000 | $717,000 | $253,000 | $168,000 |
| Free cash flow | -$24.4M | -$9.2M | -$14.4M | -$16.4M | -$12.9M |
| Total assets | $97.7M | $39.2M | $42.7M | $55.5M | $65.6M |
| Total liabilities | $69.7M | $13.8M | $21.5M | $18.6M | $16.8M |
| Total debt | $50.9M | — | $10.0M | $10.0M | $10.0M |
Shares outstanding 30.0M · Free float 38.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.